arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Revolution Medicines, Inc.

RVMD
$177.92 ▼ -41.44 (-18.89%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
32 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

Revolution Medicines, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $37.5B
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -15.3% ↗
FCF / Share $-1.85 ↘
Trailing P/E —
Price / Book 14.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-453.82M
↓ -112.6% —
Operating Margin Operating profit as % of sales
-402.5%
↓ -9.0% —
FCF / Share Free cash flow per share
$-1.85
↓ -2.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
13
Cash Quality →
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 9 years · 32 quarters